Cambridge: 24 June 2022
One Nucleus is pleased to announce an exciting collaboration with My Green Lab to support its member organisations in becoming more sustainable. We will be sign-posting the ‘My Green Lab Certification’ complimentary program and providing a discount, exclusive to One Nucleus Members, for the Accredited Professional training courses.
The purpose of this collaboration is to help drive a meaningful and sustainable change within laboratories. Training is currently available for Waste, Procurement and Green Chemistry and, later in the year, Water, Energy and Engagement…
Cambridge’s new urban innovation district welcomes Royal party and guests to celebrate its existing innovative community and mark the next stage of campus development
Cambridge, 28th June 2022: HRH The Duke of Gloucester visited the new Unity Campus development in Cambridge on Friday 24th June.
Welcomed by Nicholas Bewes, CEO, Howard Group, the developer of the site, The Duke and dignitaries, including HM Lord Lieutenant, Mrs Julie Spence OBE and The High Sheriff of Cambridgeshire, Jennifer Crompton began with a tour of The Works building. Completed in February 2020, The…
The development will provide much needed accommodation to the burgeoning life science community within the Cambridge Cluster
Cambridge, UK, 23rd June 2022: Chesterford Research Park has submitted plans to create a new three-storey building on a plot to the east of the Park to meet the high demand for life science space in the Cambridge Cluster.
Subject to planning, the approximately 60,000 sq ft multi-occupier building will be fitted with a mix of laboratory and office space and will be ready for occupation in the summer of 2024.
Named the Sidney Sussex Building…
Andy Billinton PhD appointed as Chief Scientific Officer
Expansion into larger facilities at the Babraham Research Campus
Cambridge, 23rd June 2022: Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.
Transine Therapeutics is developing a novel class of therapeutic RNAs (SINEUPs®) capable of upregulating protein expression with a superior level of control and specificity across an unprecedented range of hard-to-treat diseases, which…
A Charnwood Campus Cluster event, part of a series of events to support the growth and success of the life science organisations clustered around Charnwood Campus Science, Innovation and Technology Park
Business leaders, entrepreneurs, innovators and stakeholders gathered at Charnwood Campus to hear about new ways to encourage innovation and accelerate new product development in collaboration with the NHS and academia, understand how Employee Value Proposition and Corporate Social Responsibility are helping win the war for talent and identify some of the first easy steps on the road map to…
Scorching temperatures, sizzling burgers and great company awaited members of the Norwich Research Park community who joined Anglia Innovation Partnership LLP (AIP) at their community summer barbecue sponsored by Chadwicks and Fortus.
The event was held on the grass and terrace area just outside the Centrum building attended by over 200 guests, from businesses and park partner organisations, who joined in the fun with networking, games and great food from the Genuine Dining Company.
Roz Bird, the new Chief Executive of Anglian Innovation Partnership commented, “Well done to the whole AIP team…
Expansion of European business development team supports next phase of growth for Metrion’s ion channel drug discovery services
Cambridge, UK, 09 June 2022 - Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion channel discovery services, the appointment follows the recent creation of a Client Services team as Metrion expands its operations and enhanced drug discovery capabilities, internationally.…
KISS Communications announced today its merger with digital agency Isle Interactive, adding
significant resources and strengthening its position as a leading creative agency.
The merger gives the award-winning agency the foundation to achieve its ambitious growth plans and
broaden and strengthen its offer across marketing and brand strategy, campaign development, inmarket
activation and digital delivery – with creativity at its heart.
The newly combined team will add even more value and expertise to the agency’s blue-chip national
and international clients operating within the science,…
Prof. Claire Thompson, multi award-winning CEO of Agility Life Sciences, has been recognised as one of the Top 10 Leaders in the field of small molecules on the 2022 Medicine Maker Power List.
Every year, leading life sciences publication the Medicine Maker asks its readers to nominate the influential people making the most impact in the drug-making space, celebrating captains in small molecules, biopharmaceuticals, and advanced therapy. The aim of the Power List is to bring the talent, passion and experience of these inspirational leaders into the limelight, showcasing the drug development…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY
Development of stable injectable high concentration formulations for its proprietary products
Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.
Under the terms of the agreement, Arecor will use its proprietary formulation technology…